Abstract
Objectives/Goals: The objective of the Clinical and Translational Science Awards (CTSA) Program Collaborative and Innovative Acceleration (CCIA) Award Initiative is to support synergistic collaborations to develop, demonstrate, and sustainably implement innovative solutions across and beyond the CTSA Consortium. Methods/Study Population: All CCIA awards between 2016 and 2022 were reviewed and analyzed by Fiscal year, activity code, and research area using NIH analytical tools and platforms. Subject matter experts categorized each award by research topics, study populations, stage of translational science, and innovation type. The number and type of collaborating organizations were noted and major accomplishments and expected outcomes were summarized. Results/Anticipated Results: Between FY2016 and FY2022, NCATS funded 37 U01 and 18 R21 CCIA awards including >90 different public and private partnering organizations. CCIA awards spanned all stages of translation including preclinical (26%), clinical (36%), implementation (31%), and public health research (7%). Of the 55 CCIA awards, 31% focused on urgent public health needs and 25% were designed to address health disparities. Broadly, types of innovations included: Data science-related projects (18%), clinical care innovations (15%), biomarker or clinical outcome assessments (13%), digital health solutions (11%), therapeutic development (11%), therapeutic discovery (9%), education and training (7%), diagnostic tools (5%), software tools (5%), or tools for clinical research (5%). In total, >735 publications cited CCIA awards. Discussion/Significance of Impact: For >8 years, the CCIAs have brought together researchers from diverse scientific disciplines across the nation to speed the development of new health solutions with broad impact. Advancements in genomic screening, for example, have led to policy changes while new delivery approaches have improved the quality of care for underserved populations.